Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
NCT03884075
Recruiting
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help. Objective: To find out how the liver in people with NAFLD responds to feeding, and how this relates to their response to the drug semaglutide. Eligibility: People with NAFLD and healthy volunteers ages 18 and older Design: Participants will be screened with: Medical history Physical exam... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Register for Updates
DIALYSIS-TIR Study
NCT06042153
Recruiting
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: University of North Carolina, Chapel Hill, North Carolina +4 locations
Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis
Register for Updates
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
NCT04779697
Completed
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/10/2025
Locations: The Yale Stress Center: Yale University, New Haven, Connecticut
Conditions: Obesity
Register for Updates
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
NCT05892432
Recruiting
This study is a randomized controlled trial of oral semaglutide among treatment-seeking individuals with AUD. The investigators will randomly assign 50 participants to receive semaglutide (titrated to 7 milligrams (mg) per day) or matched placebo for 8 weeks. The primary aims are to assess the safety and tolerability of semaglutide in this population and to evaluate its effects, relative to placebo, on alcohol cue-elicited craving and alcohol consumption.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
02/06/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Alcohol Use Disorder
Register for Updates
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
NCT04788511
Completed
This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in people taking semaglutide (a new medicine) to people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama +92 locations
Conditions: Obesity
Register for Updates
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
NCT04538352
Completed
This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glycemic control (≤ 7.5%) on MDI-based regimens (≤ 80 units of insulin per day), vs. further titration of insulin therapy in those continuing MDI. Weight loss, hypoglycemic episodes, and improvement in di... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/03/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Type 2 Diabetes
Register for Updates
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227
Active Not Recruiting
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dumm... Read More
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
01/28/2025
Locations: Neighborhood Healthcare, Escondido, California +44 locations
Conditions: Obesity
Register for Updates
Anti-obesity Pharmacotherapy and Inflammation
NCT05756764
Active Not Recruiting
This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment
Gender:
ALL
Ages:
Between 35 years and 60 years
Trial Updated:
01/08/2025
Locations: LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO, New Orleans, Louisiana +1 locations
Conditions: Obesity
Register for Updates
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT04971785
Completed
The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/07/2025
Locations: University of Alabama at Birmingham Hospital, Birmingham, Alabama +241 locations
Conditions: Nonalcoholic Steatohepatitis
Register for Updates
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
NCT05671653
Terminated
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide. The effect of these GLP-1 drugs on a single dose of the common sedative medication midazolam blood levels will be measured. The effect of chronic PF-07081532 on single doses of the common stomach acid medication omeprazole, and common birth control medication blood levels will also be measured. The hypothesis is that chronic administration of the GLP-1 drugs will mini... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Obesity
Register for Updates
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
NCT05891496
Active Not Recruiting
The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease. Semaglutide is a medicine that doctors can prescribe in some countries for the treatment of type 2 diabetes and excess body weight. This study will help us understand whether semaglutide can also be used for the treatment of Alzheimer's disease. The study will last for about 77 weeks. In the first 12 weeks of treatment, participant... Read More
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
01/02/2025
Locations: Banner Sun Health Research Institute, Sun City, Arizona +9 locations
Conditions: Alzheimers Disease
Register for Updates
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
NCT05649137
Completed
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +66 locations
Conditions: Obesity, Diabetes Mellitus, Type 2
Register for Updates